Role of In Vitro Stimulation with Lipopolysaccharide on T-Cell Activation in HIV-Infected Antiretroviral-Treated Patients

Table 1

Demographic characteristics and viro-immunological parameters of the patients in study.

Characteristic	LR; (𝑛=9)	IR; (𝑛=12)	HR; (𝑛=9)
Age, years (IQR)	50 (45–56)	48 (38–60)	39 (35–44)^a
Sex, 𝐹 (%)	2 (22)	3 (25)	3 (33)
Risk factors for HIV infection
MSM, 𝑛 (%); heterosexual, 𝑛 (%); IDU, 𝑛 (%)	2 (22); 6 (67); 1 (11)	5 (42); 4 (33); 3 (25)	1 (11); 3 (33); 5 (56)
Duration of HIV infection, years (IQR)	7 (5–19)	13 (8–22)	12 (6–23)
HAART duration, months (IQR)	71 (46–141)	106 (65–149)	71 (39–132)
Diagnosis of AIDS,𝑛	4	3	2
Absolute T CD4+ cell counts, cell/μL (IQR)
at the time of study; nadir	260 (215–339); 90 (51–179)	498 (425–537); 105 (45–208)	726 (608–863)^a; 204 (56–240)
Percentage T CD4+ cell counts, % (IQR)
at the time of study; nadir	26 (16–34); 8 (5–17)	27 (22–33); 18 (13–22)	31 (25–43); 26 (22–30)
Plasma HIV RNA, log10cp/mL (IQR)
zenith; at the time of study	5.3 (4.5–5.9); 1.7	5.4 (4.1–5.7); 1.7	4.4 (3.9–5.2); 1.7
HAART regimen; Number of patients at the time of study
NRTI+PI; NRTI+NNRTI; Other	5; 2; 2	7; 4; 1	4; 3; 2

Data are presented as median and interquartile range (IQR). LR: Low Responders (CD4+<350/μL, HIV RNA <40 cp/mL); IR: Intermediate Responders (CD4+ 350–599/μL, HIV RNA <40 cp/mL); HR: High Responders (CD4+ ≥600/μL, HIV RNA <40 cp/mL); MSM: Men having sex with men; IDU: Intravenous Drug Users; HAART: highly active antiretroviral therapy; NRTI: nucleoside reverse-transcriptase inhibitor; NNRTI: nonnucleoside reverse-transcriptase inhibitor; PI: protease inhibitor. ^a𝑃<0.05 for differences among groups.